Johnson & Johnson (NYSE:JNJ) Stock Jumps 1.5% - Here's What Happened

Key Points

• Johnson & Johnson shares rose 1.5% to about $275.17, supported by strong third-quarter results: adjusted EPS of $2.59 beat estimates, while revenue increased 5.9% year over year to $25.40 billion.
• The company’s MedTech profile received a boost after J&J presented a record 26 abstracts on its Impella heart pumps, while broader strength in large pharmaceutical stocks improved sector sentiment.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $275.92 price target, though potential 2027 earnings pressure, premium valuation and renewed investor-litigation scrutiny could limit upside.

Shares of Johnson & Johnson (NYSE:JNJ - Get Free Report) rose 1.5% during mid-day trading on Thursday. The company traded as high as $278.05 and last traded at $275.17. Approximately 5,991,073 shares traded hands during trading, a decline of 25% from the average daily volume of 7,956,292 shares. The stock had previously closed at $271.04.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s strong third-quarter performance continues to support the stock. The company previously reported adjusted EPS of $2.59, ahead of the $2.53 consensus estimate, while revenue of $25.40 billion rose 5.9% year over year and narrowly exceeded expectations. Analysts expect full-year 2026 EPS of approximately $11.12, within management’s $11.05–$11.15 guidance range. Johnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its Earnings
• Positive Sentiment: Johnson & Johnson presented a record 26 abstracts at the 2026 Transcatheter Cardiovascular Therapeutics conference, adding to more than two decades of data on the safety, efficacy and cost-effectiveness of its Impella heart pumps. The disclosures reinforce the growth and competitive positioning of the company’s medtech portfolio. Record 26 Abstracts at TCT 2026
• Positive Sentiment: Broader strength among large pharmaceutical companies is helping sector sentiment. Merck’s earnings beat and higher outlook, along with strong performance from Eli Lilly, place JNJ among several major healthcare names attracting investor interest. Merck, Eli Lilly and Johnson & Johnson Market Update
• Neutral Sentiment: Analyst coverage remains generally constructive, but investors are questioning whether JNJ’s recent gains and premium valuation adequately reflect future cash-flow growth. Potential earnings pressure in 2027 could limit further upside. Johnson & Johnson Stock Trades at a Discount Following Its 97% Run
• Negative Sentiment: Pomerantz LLP is investigating claims on behalf of JNJ investors. The announcement does not establish wrongdoing, but renewed litigation attention may increase headline risk and investor uncertainty. Pomerantz Investor Alert Regarding Johnson & Johnson

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Bank of America restated a "neutral" rating and issued a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. HSBC upped their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research report on Thursday, September 10th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Finally, Guggenheim reiterated a "buy" rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Price Performance

The company has a market cap of $662.42 billion, a P/E ratio of 41.69, a PEG ratio of 2.61 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The company has a fifty day simple moving average of $265.60 and a 200-day simple moving average of $246.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm's quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 64,515 shares of company stock worth $17,271,766 over the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of JNJ. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $28,000. Matrix Trust Co lifted its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $43,000. Hanseatic Management Services Inc. acquired a new position in Johnson & Johnson in the 3rd quarter valued at $52,000. Finally, Polaris Financial Partners purchased a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $56,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.